Vinod Dasa, MD, and Michael Hartman, MD, performed the first two U.S. procedures using CartiHeal's Agili-C implant at Louisiana State University Health New Orleans School of Medicine.
Here are three things to know:
1. CartiHeal's proprietary implant is designed for joint surface lesion treatment.
2. The first two U.S. patients were enrolled in the Agili-C Investigational Device Exemption pivotal study.
3. In Europe and Israel, 80 patients have been enrolled and treated in the study, which aims to demonstrate Agili-C's superiority over microfracture and debridement to treat cartilage or osteochondral defects in the knee.